 Under a named patient compassionate use approval by the Israeli Ministry of Health, Lineage Cell Therapeutics Incs NYSE: LCTX OpRegen has been used to treat a patient suffering from adult-onset vitelliform macular dystrophy AVMD at Hadassah-Hebrew University Medical Center in Jerusalem. The patient was presented with sudden and severe visual acuity decreases in one eye. 